China Spends 84% Of Health Expenses On Treatment, 2% On Prevention
This article was originally published in PharmAsia News
Ministry of Health’s surveys found that Tianjin city and Gansu province invested, on average, 84% of healthcare expenses in medical treatment, 13% in auxiliary medical and drug retail services, and only 2% in disease prevention.
You may also be interested in...
Aurobindo has agreed to sell its US-based Natrol dietary supplements business at a significant premium to the $132.5m it paid in late 2014, as the Indian firm continues to drive into complex formulations in the US, including injectables and biosimilars.
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.
With many competitor programs on hold during the COVID crisis, L’Oreal dialed up its media investments and launched products over the summer that were postponed from the first quarter, resulting in a return to growth in the firm’s third quarter led by Professional Products and Active Cosmetics.